Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20263872 | 0.97 | CNR1 (0.40) | NPC1POLBMAPTCNR1CNR2 | |
| SCHEMBL20264287 | 0.95 | P2RX3 (0.43) | NPC1POLBMAPTCNR1CNR2 | |
| SCHEMBL20264010 | 0.94 | POLB (0.37) | NPC1POLBMAPTCNR1CNR2 | |
| SCHEMBL20264259 | 0.93 | POLB (0.38) | NPC1POLBMAPTSRCP2RX3 | |
| SCHEMBL26962032 | 0.92 | POLB (0.41) | NPC1POLBMAPTSRCP2RX3 | |
| SCHEMBL20264297 | 0.91 | POLB (0.40) | NPC1POLBMAPTSRCP2RX3 | |
| SCHEMBL20264071 | 0.91 | POLB (0.36) | NPC1POLBMAPTCNR1CNR2 | |
| SCHEMBL20264373 | 0.91 | POLB (0.36) | NPC1POLBMAPTCNR1CNR2 | |
| SCHEMBL29796994 | 0.91 | POLB (0.41) | NPC1POLBMAPTSRCP2RX3 | |
| SCHEMBL26961926 | 0.91 | POLB (0.41) | NPC1POLBMAPTSRCP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | APEIRON BIOLOGICS AG (AT) | 2019-11-12 | — | — | US | disclosed |
| EP-3265463-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS AG (AT) | 2018-12-19 | — | — | EP | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | APEIRON BIOLOGICS GMBH (AT) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472341-B2 | Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases | CCNT2, HRH4, HRH3 | NPC1 563/4885POLB 3325/4885MAPT 2443/4885 |
| US-20180170888-A1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES | CCNT2, HRH4, HRH3 | NPC1 563/4885POLB 3325/4885MAPT 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.